Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse

TMC435 for the treatment of chronic hepatitisC

(2012) Sudeep Tanwar et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Association between interleukin-28B-related genetic variants and liver histopathology differs between hepatitis C virus genotypes

(2012) Karolina Rembeck et al.   HEPATOLOGY

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study

(2012) Christophe Moreno et al.   JOURNAL OF HEPATOLOGY

Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3

(2012) Karolina Rembeck et al.   PLoS One

Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3

(2012) Åsa Alsiö et al.   PLoS One

Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C

(2012) Peer Brehm Christensen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment

(2011) Annarosa Floreani et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

IL28Bgenetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

(2011) Amir Moghaddam et al.   HEPATOLOGY

IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes

(2011) Pierre-Yves Bochud et al.   HEPATOLOGY

IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C

(2011) P.-Y. Bochud et al.   JOURNAL OF HEPATOLOGY

Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus

(2011) Magnus Lindh et al.   JOURNAL OF INFECTIOUS DISEASES

IL28Bpolymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1

(2011) M. Lindh et al.   JOURNAL OF VIRAL HEPATITIS

Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms

(2011) Martin Lagging et al.   PLoS One

Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection

(2010) Martin Lagging et al.   HEPATOLOGY

Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection?

(2010) Martin Lagging et al.   JOURNAL OF HEPATOLOGY

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

(2009) Thierry Poynard et al.   GASTROENTEROLOGY

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients

(2009) Robert Flisiak et al.   HEPATOLOGY

Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C

(2009) Galia Askarieh et al.   HEPATOLOGY

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection

(2008) Alessandra Mangia et al.   HEPATOLOGY

Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

(2008) Martin Lagging et al.   HEPATOLOGY

Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection

(2008) Martin Lagging et al.   HEPATOLOGY